熱門資訊> 正文

Corbus Pharmaceuticals股价下跌17%，每股13美元，股价为7500万美元

2025-10-31 18:10

Corbus製藥控股(CRBP) 0

Corbus Pharmaceuticals (CRBP) priced an underwritten public offering of ~4.74M shares at $13.00 per share and pre-funded warrants to purchase ~1.03M shares, for a total public offering size of ~$75M.
The underwriters a 30-day option to purchase up to an additional 865,384 shares of its common stock on the same terms and conditions.
The offering is expected to close on or about November 3, 2025.
Corbus intends to use the net proceeds of the offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes.
The stock price dropped ~17% on Friday during pre-market hours of trading.

More on Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel - Slideshow
Corbus Pharmaceuticals announces proposed public offering to fund clinical pipeline
Corbus higher as FDA issues another fast track tag for lead asset
Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。